Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 7194 matches for

Facebook co-founder Mark Zuckerberg recently posted a photo on the social networking site of his two-month-old daughter in the doctor’s surgery waiting to be vaccinated. It provoked a storm on social media, with millions of people commenting on the pros and cons of vaccination. So was Zuckerberg right to have his child vaccinated?

Similar stories

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.

World's first Phase II Nipah virus vaccine trial launch

Global Consortium Launched to Develop Next-Generation Malaria Vaccine

First Volunteer Receives Lassa Fever Vaccine in Cutting-edge Oxford Trial

HRH The Duke of Gloucester Visits University of Oxford’s Cutting-Edge Vaccine Facilities

Oxford vaccine against deadly Nipah virus granted EMA PRIME designation for the first time